Colon Cancer

Clinical Trials

Below is a list of Colon Cancer clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Multinational National Institutes of Health-Sponsored Colon Cancer Family Registry
This study is being done to identify individuals from families that have experienced one or more instances of colon cancer, in order to study these families in detail. The current understanding of the environmental and genetic factors that contribute to the development of colon cancer are poorly understood. By carefully evaluating a large number of families that have experienced one or more instances of colon cancer it may be possible to identify factors (environmental, genetic or both) that lead to increase risk of colon cancer. The Mayo Clinic and other medical centers are working together to create a National Cancer Institute Cooperative Family Registry for Colon Cancer Studies, which consists of gathering together information and biological specimens (blood and tumor tissue) from carefully studied families with colon cancer in order to facilitate colon cancer research.
Read more

E5202 "Phase III Study Comparing 5-FU (5-fluorouracil) Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab (Avastin) in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers"
At the present time, researchers do not know if chemotherapy, for stage II colon cancer, can help reduce the chances that a patient's cancer might come back. Currently, the standard of care for individuals with this type of cancer is to receive no chemotherapy.

The research staff believe there may be biological features in the tumor (called tumor markers or markers) that will help to identify patients who should receive chemotherapy. The tumor markers to be used in this research study were selected based on experiments that showed they might identify patients who have a greater chance of having their cancer come back. The cancer researchers who designed this trial are trying to determine if patients with these tumor markers have a better chance of being cured if they receive chemotherapy after surgery. Therefore, the decision to give the patient chemotherapy will be made after the patient's tumor has been tested for the tumor markers. If those tumor markers suggest the patient may be at higher risk for the cancer coming back, the patient will get chemotherapy. However, if the tumor markers suggest the patient may be at a lower risk for the cancer coming back, the patient will not receive chemotherapy but they will be seen by their doctor with regularly scheduled visits.

This study is being done to:
- Determine whether specific biological features (often called tumor markers or markers) seen in tests done on a tumor (found in the colon) can be used to predict recurrence of tumors in patients with stage II colon cancer.
- Compare the effects (good and bad) of a combination of chemotherapy drugs, when given with and without a new drug, bevacizumab, on patients with stage II colon cancer at high-risk for recurrence.

The chemotherapy drugs given in this study are 5-fluorouracil (5-FU), leucovorin and oxaliplatin. The researchers want to see if adding bevacizumab to the other cancer-fighting agents is better for treating colon cancer patients, who may be at increased risk for recurrence based on the markers shown in their tumor. The research staff also want to see if adding bevacizumab will help prevent the cancer from coming back. The United States Food and Drug Administration (FDA) considers the use of bevacizumab to be investigational for treating Stage II colon cancer.
Read more

Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (N0147)
This research study is being done in patients who have had surgery for colon cancer to: Find out the effectiveness of the following six different combinations of drugs in stopping the return of your colon cancer these treatments, namely cetuximab (C225), irinotecan (CPT-11) and oxaliplatin (OXAL), are considered investigational in the stage of colon cancer that you have. These drugs are given in combination with standard chemotherapy drugs called 5-fluorouracil (5-FU) and leucovorin (CF).
Read more

Phase 3 Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (Erbitux) with or without Bevacizumab (Avastin) as Second-Line Therapy for Patients With Metastatic Colorectal Cancer who Have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX
The purpose of this study is to find out if the addition of bevacizumab improves response and survival.

Bevacizumab is the common name for the commercial drug Avastin. The bevacizumab used in this trial, however, is for use in research studies only and may be made at locations different from those where Avastin is made. Although some differences may exist, bevacizumab for research use and the commercial drug, Avastin, are manufactured by a similar process, meet similar standards for final product testing, and are expected to be very similar in safety and effectiveness.
Read more

Study of Celebrex and Selenium to Decrease the Risk of Developing Recurrent Colon Polyps
The Division of Gastroenterology is currently recruiting participants between the ages of 40 and 80 in a research study to determine whether treatment with celecoxib (Celebrex), or selenium, or the combination of celecoxib and selenium can decrease the risk of developing recurrent polyps. Eligible particpants must have had a colonoscopy where an adenomatous(precancerous)polyp was found and removed.
Read more